Skip to content
A scientist in a GMP cleanroom holding a vial of amber adipose-derived stem cell suspension

Apgujeong, Seoul · Stem cell R&D company

EHL Bio Hospital: Korea's adult stem cell centre with its own research institute and GMP labs

A full-stack cell therapy hospital: 6,000 GMP lots a year, four stem cell drugs in development and a cell centre in Apgujeong, Seoul

Founded
2012
GMP capacity
6,000 lots/yr
Pipeline drugs
4

Quick answer

EHL Bio Hospital (㈜이에이치엘바이오) is a Korean hospital specialising in adult stem cell therapy, founded in 2012. What sets it apart from ordinary stem cell clinics is that the hospital runs its own research institute in Uiwang, Gyeonggi-do and its own international-standard laboratories: two in-house GMP plants culturing more than 6,000 lots a year in CLASS 100 clean rooms, inspected by Korea's MFDS and holding a CPC licence from Japan's Ministry of Health, Labour and Welfare. Patient care centres on the EHL Cell Center at 136 Apgujeong-ro in Gangnam, Seoul. Core technology is autologous adipose-derived stem cells, behind a four-drug pipeline: ADSTEM for atopic dermatitis (Phase 3 IND filed in 2024), KDSTEM for chronic kidney disease (Phase 1 from 2023), RASTEM for rheumatoid arthritis (preparing Phase 1) and PDSTEM for Parkinson's disease (preclinical). It also produces EHL-STEM conditioned media with an internationally registered INCI name, works on NK, T, dendritic and iNKT immune cells and exosomes, and publishes 11 patent filings, alongside a network of roughly 100 partner hospitals in Korea and 50 overseas.

Who is EHL Bio, and what is it actually good at?

The five pillars below are the company's own stated strengths from its corporate page, restated here and flagged as company claims rather than independently verified conclusions.

Stable stem cell harvesting, isolation and culture technology

  • In-house culture know-how backed by its own patents
  • The company states a stem cell recovery rate about 1,000× higher than competitors
  • Minimised gap in cell viability before and after cryopreservation
  • Running what the company calls Korea's first repeated intravenous dosing trial

Its own top-tier GMP facilities

  • Own autologous stem cell culture, banking and quality-control system
  • Clean rooms maintained at CLASS 100
  • Dedicated stem cell storage tanks and banking system
  • Capacity of more than 6,000 lots a year (about 500 lots a month)

Research and partner-hospital network

  • Joint research with Korean and overseas universities
  • Around 100 partner hospitals inside Korea
  • Around 50 overseas partner hospitals for cross-border treatment

A broad cell-therapy development portfolio

  • Exosome-based therapeutics
  • Pharmaceuticals derived from stem cell conditioned media
  • Immune cells: NK, T, dendritic and iNKT

Deep experience in cosmeceuticals

  • Products aimed at aesthetic and dermatology clinic patients
  • Launched cosmetics containing 97% human adipose stem cell conditioned media

Pricing and cell banking

The figures below are reference prices from partner clinics/hospitals that use EHL Bio cells, not a direct-to-patient list price from the company. Actual prices depend on the hospital and package chosen.

Standard MSC package (partner-clinic reference)

Reference MSC package

Starting price

35,000 USD

50,000,000 KRW

Sessions / total cells

3 sessions

900,000,000 cells (300,000,000 cells/session)

Cell banking up to

10 years

Cost per million cells

0 USD

55,556 KRW

Indicative starting price from partner clinics/hospitals using cells from EHL Bio Hospital's GMP labs, not a direct-to-patient list price.

EHL Bio Stem Cell MSC package summary
ItemDetail
Starting price35,000 USD
Approximate price (KRW)≈ 50,000,000 KRW
Sessions3 sessions
Cells per session300,000,000 cells
Total cells900,000,000 cells
Rate per million cells0 USD ≈ 55,556 KRW
Cell banking term10 years

What the package includes

  • Adipose tissue harvesting and stem cell isolation in the GMP facility
  • Cell culture plus quality control (viability, sterility testing)
  • Three administrations of 300 million cells each
  • Banking of remaining cells for up to 10 years

What is not included

  • Physician consultation, blood work and pre-treatment screening
  • VAT and any hospital administrative fees
  • Travel, accommodation, interpreter and international patient coordination
  • Any add-on treatments outside the package

Pricing notes and conditions

  1. Prices are indicative per patient as at the capture date and vary by partner hospital and exchange rate.
  2. A physician assessment and approval is required first; some patients are not eligible.
  3. Banking is counted from the harvest date; renewal fees may apply after the term.
  4. Outcomes vary between individuals and no clinical result is guaranteed.
  5. Always request a written quotation from the hospital before making any payment.

Exchange rate used: 1 KRW ≈ 0.0007 USD (captured 2026-08-25). Prices exclude tax and physician consultation fees. Request a written quotation from the hospital before transferring any payment.

What is in the pipeline, and how far has each drug got?

A row of autologous stem cell injection vials on a white laboratory bench

All four are investigational products, not services you can walk in and buy. Status is taken from the company's pipeline and history pages.

ADSTEM inj.

에이디스템주

Moderate-to-severe subacute and chronic atopic dermatitis

  1. Candidate
  2. Preclinical
  3. Phase 1
  4. Phase 2
  5. Phase 3
Cell source
Autologous adipose-derived mesenchymal stem cells
Route
Intravenous injection, two repeated doses
Status
Phase 1 complete · Phase 2 finished 2023 · Phase 3 IND filed 2024
Note
Phase 2 ran at Chung-Ang University Hospital and five other centres; the company describes it as Korea's first intravenous autologous adipose stem cell trial.

RASTEM inj.

알에이스템주

Moderate-to-severe rheumatoid arthritis

  1. Candidate
  2. Preclinical
  3. Phase 1
  4. Phase 2
  5. Phase 3
Cell source
Autologous adipose-derived mesenchymal stem cells
Route
Intravenous injection, repeated dosing
Status
Preclinical complete, preparing Phase 1
Note
Not an approved treatment available to the public.

PDSTEM inj.

피디스템주

Parkinson's disease

  1. Candidate
  2. Preclinical
  3. Phase 1
  4. Phase 2
  5. Phase 3
Cell source
Autologous adipose-derived mesenchymal stem cells
Route
Intravenous injection, repeated dosing
Status
Preclinical stage, in progress
Note
Research stage; no concluded human efficacy data yet.

KDSTEM inj.

케이디스템주

Chronic kidney disease

  1. Candidate
  2. Preclinical
  3. Phase 1
  4. Phase 2
  5. Phase 3
Cell source
Autologous urine-derived mesenchymal stem cells
Route
Intravenous injection, repeated dosing
Status
Phase 1 IND approved and started in 2023 · selected for Korea's multi-ministry regenerative medicine programme in 2022 and 2024
Note
Urine-derived stem cells express Klotho, a protein linked to antioxidant activity, cell-senescence control and angiogenesis.

What can EHL Bio's GMP plants actually do?

A Korean biotech GMP cell culture suite with rows of CO2 incubators and a gowned technician
Capacity
6,000 lots/yr
Per month
500 lots
Clean room
CLASS 100
Partner hospitals
100+ / 50+
  1. 2015.10

    First GMP centre completed

  2. 2016.05

    GMP inspection by Korea's MFDS

  3. 2017.07

    CPC licence from Japan's Ministry of Health, Labour and Welfare

  4. 2019.04

    Second GMP centre completed (about 500 lots a month)

  5. 2021

    Korea's licence No.1 for human cell management and the country's first cell-processing facility licence

Which disease groups does the company target?

This is the list of disease groups the company names on its Cure pages as research targets. It does not mean an approved product exists for each of them.

  • Alzheimer's disease (dementia)

    Brain and nervous system

  • Degenerative arthritis

    Bone and joint

  • Diabetes

    Endocrine and metabolic

  • Erectile dysfunction

    Reproductive

  • Liver cirrhosis

    Hepatic

  • Myocardial infarction

    Cardiovascular

  • Chronic obstructive pulmonary disease

    Respiratory

  • Autoimmune disease

    Immune

  • Atopic dermatitis

    Dermatological

What does the immune cell side cover?

Microscope view of cultured mesenchymal stem cells fluorescing teal and violet on black

NK cells

Attack virus-infected and tumour cells

Macrophages

Phagocytose bacteria, clear debris and present antigen

iNKT cells

Regulate and reinforce immunity across several conditions

Dendritic cells

Present cancer-specific antigen

B lymphocytes

Produce antibodies

T lymphocytes

Bind histocompatible antigen and attack tumour cells

What is EHL-STEM conditioned media?

Media generated while culturing human adipose stem cells, registered under the INCI name “Human Adipose Stromal Cell Conditioned Media” (application 5-09-2014-2745), with VEGF, FGF, TGF, PDGF, HGF, EGF as its headline growth factors. The figures below come from testing by Dermapro Co., Ltd., January 2016 at cell level, not from a human clinical trial.

Intracellular melanin
down 49%
Tyrosinase activity
down 45%
DOPA oxidation
down 22%
Collagen synthesis
up 9× (3.69 → 33.32 mg/g)
Collagenase activity
down 47%

Patents and published papers

The company publishes 11 patent filings with their application numbers, all traceable in Korea's KIPRIS patent database.

  1. Novel thiazolidinedione derivatives and their use

    2012-08-02 · 10-1172638

    Inhibits 15-PGDH, which degrades prostaglandin; applicable to cardiovascular, gastrointestinal and kidney disease and to hair-loss prevention

  2. Adipose harvesting and SVF isolation kit

    2016-01-20 · 10-2016-0007049

    Makes fat harvesting and stem cell isolation a single simplified workflow

  3. Composition of cells treated with a 15-PGDH inhibitor (atopic dermatitis)

    2016-10-26 · 10-2016-0139967

    Pharmaceutical composition for preventing or treating atopic disease

  4. Composition comprising cells treated with 15-PGDH inhibitor (US filing)

    2016-10-27 · 15/771853

    Overseas filing of the same technology

  5. Composition of cells treated with a 15-PGDH inhibitor (rheumatoid arthritis)

    2018-01-04 · 10-2018-0001149

    Extends the application to rheumatoid arthritis

  6. Cosmetic composition containing stem cell conditioned media and its production method

    2018-03-16 · 10-2018-0030906

    Conditioned media from 3D hypoxic culture for wound healing, skin improvement and hair loss

  7. Mass culture method for adipose stem cells expressing FoxO

    2018-12-28 ·

    Scales up production of cells expressing anti-ageing factors

  8. Medium composition for culturing urine-derived stem cells

    2019-11-04 · 10-2019-0139702

    Media for isolating and culturing urine-derived stem cells

  9. Mass culture of adipose stem cells expressing anti-ageing factors

    2020-02-03 · 10-2020-0012437

    Covers Foxo1, Foxo3a and Klotho plus the proliferation medium

  10. Stem cell derived exosome composition for skin regeneration, brightening, antioxidation and wound healing

    2021-02-17 · 10-2021-0021026

    Exosomes from urine-derived stem cells for cosmetic or pharmaceutical use

  11. Urine-derived stem cells with enhanced kidney-disease activity and the resulting cell therapy composition

    2021-09-29 · 10-2021-0129299

    The technology feeding the KDSTEM kidney programme

  • Human adipose tissue derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation

    2016-11-19

  • Human adipose tissue derived mesenchymal stem cells attenuate atopic dermatitis by regulating the expression of MIP2, miR122a-SOCS1 axis and Th1/Th2 responses

    2016-11-19

Inside the EHL Bio Cell Center in Gangnam, Seoul

Photographs taken on site: the cell centre building, waiting lounge, reception, private infusion suite, twin recovery room and en-suite bathroom — so you know the standard of care before you travel. Tap a photo to enlarge it (arrow keys to browse).

The EHL Bio Cell Center building in Gangnam, Seoul
The “EHL BIO CELL CENTER” facade signage
Gallery-style waiting lounge with original art and a sculptural mobile
Reception desk of the EHL Bio Cell Center
Private single-bed cell infusion suite
Twin-bed recovery room for patients travelling in pairs
En-suite bathroom and marble vanity inside the patient suite

Photographed by the Khunkim.com team at the EHL Bio Cell Center, Seoul

EHL Bio hospital introduction and educational videos

Every clip comes from EHL Bio's official YouTube channel, which speaks Korean and English. Titles are translated, and the key clips carry a summary, key points and a condensed transcript so you can read the content without watching end to end.

Videos

Reviews and guides from the hospital's official channel — swipe for more

Channel
30 clips

Clip summaries

Read the key takeaways from each clip without watching it end to end

EHL Bio hospital introduction (brand film teaser)

The short introduction film to EHL Bio: a cell therapy hospital that runs its own research institute and GMP laboratories, built on the idea that cell therapy starts with the quality of the cells you manufacture yourself.

Key points

  • EHL Bio is a cell therapy hospital with its own research institute and GMP labs
  • Its position: cell quality controlled end to end, from lab to patient
  • The brand film frames a long-term goal of regeneration using the patient's own cells
Clip transcript

The teaser opens inside the laboratory and cell culture rooms, framing the start of treatment at EHL Bio not in the consultation room but in the lab where cell quality is controlled.

It then links research to clinical use: adipose-derived stem cells from the patient, immune cells, and downstream products such as conditioned media and exosomes.

It closes on the message that the company's goal is to make regenerative medicine both accessible and verifiable against standards.

Questions from this clip

Pick a question to jump the player to the relevant moment

Use arrow up/down to move between questions, Enter to expand

  • What does this clip say about eHL Bio is a cell therapy hospital with its own research institute and GMP labs?

    EHL Bio is a cell therapy hospital with its own research institute and GMP labs — The short introduction film to EHL Bio: a cell therapy hospital that runs its own research institute and GMP laboratories, built on the idea that cell therapy starts with the quality of the cells you manufacture yourself.

  • What details are covered on its position: cell quality controlled end to end, from lab to patient?

    Its position: cell quality controlled end to end, from lab to patient — The short introduction film to EHL Bio: a cell therapy hospital that runs its own research institute and GMP laboratories, built on the idea that cell therapy starts with the quality of the cells you manufacture yourself.

  • Why does the brand film frames a long-term goal of regeneration using the patient's own cells matter?

    The brand film frames a long-term goal of regeneration using the patient's own cells — The short introduction film to EHL Bio: a cell therapy hospital that runs its own research institute and GMP laboratories, built on the idea that cell therapy starts with the quality of the cells you manufacture yourself.

EHL Bio PR film: where medicine meets science — ACT platform, clinical pipeline and GMP plants

The full corporate film explains EHL Bio's three pillars: the ACT cell therapy platform, the research pipeline of drug candidates in clinical development, and the GMP plants that manufacture the cells used in treatment.

Key points

  • The ACT platform is the core linking research to actual patient treatment
  • Stem cell drug candidates are in clinical trials across several indications
  • In-house GMP plants make quality control and lot traceability possible
Clip transcript

The film starts by asking what makes one cell therapy provider different from another. EHL Bio's answer is the manufacturing process and laboratory standard, not merely the type of cell used.

The next section tours the GMP production line: clean rooms, contamination testing, cell viability checks and full record-keeping for traceability.

The final part covers the research pipeline — osteoarthritis, neurological disease and immune-related conditions — stressing that clinical trials are what make outcomes credible.

Questions from this clip

Pick a question to jump the player to the relevant moment

Use arrow up/down to move between questions, Enter to expand

  • What does this clip say about the ACT platform is the core linking research to actual patient treatment?

    The ACT platform is the core linking research to actual patient treatment — The full corporate film explains EHL Bio's three pillars: the ACT cell therapy platform, the research pipeline of drug candidates in clinical development, and the GMP plants that manufacture the cells used in treatment.

  • What details are covered on stem cell drug candidates are in clinical trials across several indications?

    Stem cell drug candidates are in clinical trials across several indications — The full corporate film explains EHL Bio's three pillars: the ACT cell therapy platform, the research pipeline of drug candidates in clinical development, and the GMP plants that manufacture the cells used in treatment.

  • Why does in-house GMP plants make quality control and lot traceability possible matter?

    In-house GMP plants make quality control and lot traceability possible — The full corporate film explains EHL Bio's three pillars: the ACT cell therapy platform, the research pipeline of drug candidates in clinical development, and the GMP plants that manufacture the cells used in treatment.

Redefining the standards of stem cell therapy: inside EHL Bio's world-class GMP plant (English)

An English-language tour of EHL Bio's GMP laboratories, explaining how a CLASS 100 cell manufacturing plant controls air, temperature and contamination — and why those standards determine the quality of the cells that reach the patient.

Key points

  • CLASS 100 clean rooms control airborne particles to prevent contamination
  • Every lot is tested for sterility, endotoxin and viability before release
  • Measurable cell quality is what separates standard-compliant therapy from the rest
Clip transcript

The clip explains that therapeutic cells must be cultured in an environment where airborne particles, pressure and temperature are controlled, because even minor contamination invalidates the whole lot.

It then walks the workflow: receiving the adipose tissue sample, isolating cells, expanding them, quality testing, then temperature-controlled filling and transport.

The takeaway: GMP is not paperwork but the condition that makes cell count, viability and safety comparable from lot to lot.

Questions from this clip

Pick a question to jump the player to the relevant moment

Use arrow up/down to move between questions, Enter to expand

  • What does this clip say about cLASS 100 clean rooms control airborne particles to prevent contamination?

    CLASS 100 clean rooms control airborne particles to prevent contamination — An English-language tour of EHL Bio's GMP laboratories, explaining how a CLASS 100 cell manufacturing plant controls air, temperature and contamination — and why those standards determine the quality of the cells that reach the patient.

  • What details are covered on every lot is tested for sterility, endotoxin and viability before release?

    Every lot is tested for sterility, endotoxin and viability before release — An English-language tour of EHL Bio's GMP laboratories, explaining how a CLASS 100 cell manufacturing plant controls air, temperature and contamination — and why those standards determine the quality of the cells that reach the patient.

  • Why does measurable cell quality is what separates standard-compliant therapy from the rest matter?

    Measurable cell quality is what separates standard-compliant therapy from the rest — An English-language tour of EHL Bio's GMP laboratories, explaining how a CLASS 100 cell manufacturing plant controls air, temperature and contamination — and why those standards determine the quality of the cells that reach the patient.

Patient case EP1: hope from immune cell therapy in small lymphocytic lymphoma

The first audiobook-style patient story: a person with small lymphocytic lymphoma who received immune cell therapy alongside standard care.

Key points

  • Immune cell therapy is used as adjunctive care, not a replacement for standard treatment
  • Follow-up relies on blood results and assessment by the treating physician
  • Outcomes are individual and depend on disease stage and general condition

Questions from this clip

Pick a question to jump the player to the relevant moment

Use arrow up/down to move between questions, Enter to expand

  • What does this clip say about immune cell therapy is used as adjunctive care, not a replacement for standard treatment?

    Immune cell therapy is used as adjunctive care, not a replacement for standard treatment — The first audiobook-style patient story: a person with small lymphocytic lymphoma who received immune cell therapy alongside standard care.

  • What details are covered on follow-up relies on blood results and assessment by the treating physician?

    Follow-up relies on blood results and assessment by the treating physician — The first audiobook-style patient story: a person with small lymphocytic lymphoma who received immune cell therapy alongside standard care.

  • Why does outcomes are individual and depend on disease stage and general condition matter?

    Outcomes are individual and depend on disease stage and general condition — The first audiobook-style patient story: a person with small lymphocytic lymphoma who received immune cell therapy alongside standard care.

Clozome: exosome skincare with visible change in nine days

An introduction to Clozome, EHL Bio's exosome skincare line: how exosomes from stem cell conditioned media act on the skin, and what can be measured in the first nine days.

Key points

  • Exosomes are cell-derived signalling vesicles, not cells themselves
  • The aim is reducing inflammation and prompting repair in the upper skin layers
  • Continuous use plus objective skin measurement, not just perception, is advised

Questions from this clip

Pick a question to jump the player to the relevant moment

Use arrow up/down to move between questions, Enter to expand

  • What does this clip say about exosomes are cell-derived signalling vesicles, not cells themselves?

    Exosomes are cell-derived signalling vesicles, not cells themselves — An introduction to Clozome, EHL Bio's exosome skincare line: how exosomes from stem cell conditioned media act on the skin, and what can be measured in the first nine days.

  • What details are covered on the aim is reducing inflammation and prompting repair in the upper skin layers?

    The aim is reducing inflammation and prompting repair in the upper skin layers — An introduction to Clozome, EHL Bio's exosome skincare line: how exosomes from stem cell conditioned media act on the skin, and what can be measured in the first nine days.

  • Why does continuous use plus objective skin measurement, not just perception, is advised matter?

    Continuous use plus objective skin measurement, not just perception, is advised — An introduction to Clozome, EHL Bio's exosome skincare line: how exosomes from stem cell conditioned media act on the skin, and what can be measured in the first nine days.

A new future for atopic dermatitis treatment: stem cells

An educational clip on a new direction for atopic dermatitis care using stem cells, covering the immune-modulating mechanism and the limits still pending clinical trial results.

Key points

  • Atopic dermatitis involves an over-reactive immune response
  • Stem cells are studied for immune modulation rather than symptom-level treatment
  • Clinical trial results are still needed to confirm efficacy and long-term safety

Questions from this clip

Pick a question to jump the player to the relevant moment

Use arrow up/down to move between questions, Enter to expand

  • What does this clip say about atopic dermatitis involves an over-reactive immune response?

    Atopic dermatitis involves an over-reactive immune response — An educational clip on a new direction for atopic dermatitis care using stem cells, covering the immune-modulating mechanism and the limits still pending clinical trial results.

  • What details are covered on stem cells are studied for immune modulation rather than symptom-level treatment?

    Stem cells are studied for immune modulation rather than symptom-level treatment — An educational clip on a new direction for atopic dermatitis care using stem cells, covering the immune-modulating mechanism and the limits still pending clinical trial results.

  • Why does clinical trial results are still needed to confirm efficacy and long-term safety matter?

    Clinical trial results are still needed to confirm efficacy and long-term safety — An educational clip on a new direction for atopic dermatitis care using stem cells, covering the immune-modulating mechanism and the limits still pending clinical trial results.

Visceral fat, inflammation and cancer risk: four ways to cut belly fat

A health clip on how visceral fat drives chronic inflammation linked to cancer risk, with four practical ways to reduce belly fat.

Key points

  • Visceral fat releases inflammatory signals, unlike subcutaneous fat
  • Sleep, stress and sugar affect visceral fat more than people expect
  • Combining resistance training with cardio reduces visceral fat better than cardio alone

Questions from this clip

Pick a question to jump the player to the relevant moment

Use arrow up/down to move between questions, Enter to expand

  • What does this clip say about visceral fat releases inflammatory signals, unlike subcutaneous fat?

    Visceral fat releases inflammatory signals, unlike subcutaneous fat — A health clip on how visceral fat drives chronic inflammation linked to cancer risk, with four practical ways to reduce belly fat.

  • What details are covered on sleep, stress and sugar affect visceral fat more than people expect?

    Sleep, stress and sugar affect visceral fat more than people expect — A health clip on how visceral fat drives chronic inflammation linked to cancer risk, with four practical ways to reduce belly fat.

  • Why does combining resistance training with cardio reduces visceral fat better than cardio alone matter?

    Combining resistance training with cardio reduces visceral fat better than cardio alone — A health clip on how visceral fat drives chronic inflammation linked to cancer risk, with four practical ways to reduce belly fat.

Company timeline, 2012–2024

  1. 2024
    • KDSTEM selected for the multi-ministry regenerative medicine technology programme
    • Phase 3 IND filed for ADSTEM in atopic dermatitis
  2. 2023
    • KDSTEM Phase 1 IND approved for chronic kidney disease and trial started
    • ADSTEM Phase 2 completed
  3. 2022
    • Advanced regenerative medicine MOUs with Hwasun Chonnam National University, Gangnam Severance and Seoul Saesum hospitals
    • EHL Cell Center relocated to Apgujeong
  4. 2021
    • Licence No.1 for human cell management and Korea's first cell-processing facility licence
  5. 2020
    • Subsidiary EHL CELLTECH founded
  6. 2019
    • ADSTEM Phase 2 approved — the company states it is Korea's first autologous adipose IV trial
    • Cambodia branch and joint-venture cell therapy hospital opened; Indonesia office established
    • Second GMP centre built
  7. 2017
    • ADSTEM Phase 1 completed · Japanese CPC certification · Vietnam representative office · partnership with Japan's ODA Clinic
  8. 2015
    • Cell therapy GMP plant completed, research institute expanded, venture company certification
  9. 2012
    • EHL Bio life science research institute founded

Where is EHL Bio and how do you contact it?

Cell centre (Seoul)
EHL Cell Center — 136 Apgujeong-ro, EHL Building, Gangnam-gu, Seoul 06029
Subway
444 m from Apgujeong Station, exit 5
Phone
+82-2-532-9855
Fax
+82-2-514-8027
HQ & research institute
Indeokwon IT Valley, 40 Imi-ro, Bldg B #411-412, Uiwang-si, Gyeonggi-do
HQ phone
+82-2-535-9883
Overseas network
Japan, Vietnam, Cambodia, Indonesia
Open EHL Cell Center in Maps

Questions to settle before visiting the EHL Bio Cell Center

The questions Thai readers ask most about getting there, the rooms, lab documentation, total cost and risk — answered directly, with what to request in writing.

  • Where is the EHL Bio Cell Center, and how do you get there from Gangnam?

    The cell centre sits at 136 Apgujeong-ro, Gangnam-gu, Seoul — Korea's aesthetic and regenerative medicine district. Take Line 3 to Apgujeong station or the Bundang line to Apgujeong Rodeo, then walk a few minutes. From Incheon airport it is roughly 60–80 minutes by limousine bus or taxi. The hospital runs its own patient shuttle van (visible in the exterior photo); ask in advance whether your case qualifies for pick-up.

  • What are EHL Bio's rooms like, and is an overnight stay required?

    On site there are private single-bed infusion suites with en-suite bathrooms (marble basin, LED mirror, skincare amenities) and twin recovery rooms for couples or patients travelling with a carer — closer to a hotel than a ward. An intravenous cell infusion usually takes a few hours and you return to your accommodation the same day, but if fat is harvested or another procedure is combined, the doctor may extend observation. Confirm against your own treatment plan.

  • How can you verify the cells were really cultured in EHL Bio's own GMP lab?

    Ask for three documents in writing: (1) the name, address and cell-processing facility licence number of the lab that cultured the cells; (2) the per-lot quality report — cell count per dose, viability, sterility and endotoxin results; and (3) a consent form stating plainly whether this is treatment, banking or trial enrolment. Because EHL Bio's labs are hospital-owned (two GMP centres, CLASS 100 clean rooms), it can answer all three at source.

  • What should a Thai patient budget in total for EHL Bio?

    The hospital's published pricing separates harvesting, culturing, annual banking and each infusion. On top of that, budget flights, 3–7 nights in Gangnam, local transport, an interpreter if needed, and pre-infusion blood work. Ask for a fully itemised quote before transferring money, and check whether cell banking carries a recurring annual fee.

  • EHL Bio's videos are in Korean — can Thai viewers follow them?

    The original clips from the official YouTube channel are in Korean and English. On this page every title is translated into Thai and the key clips carry a summary, key points and a condensed Thai transcript, so you can read the substance without watching in full. To hear the original, turn on YouTube's auto-captions and add Thai translation.

  • Are the facility photos on this page real or supplied press images?

    They are original photographs taken by the Khunkim.com team while visiting the EHL Bio Cell Center in Gangnam, Seoul — not stock or renders. Every frame carries a bilingual caption and alt text; tap any photo to open the full-size viewer and use the arrow keys to move between images.

  • What risks and caveats should you weigh before any stem cell infusion?

    Four caveats: (1) for many conditions the evidence is still research-stage rather than an approved drug, so do not expect a cure; (2) every procedure carries risk — fat harvesting, intravenous infusion, allergic reaction, infection; (3) disclose your full medical history, medication and any cancer history to the doctor; and (4) walk away from guaranteed results or pressure to decide on the spot. This page is educational information, not personal medical advice.

Key facts

Type
Cell therapy hospital with its own research institute and GMP labs
Founded
2012
CEO
Lee Hong-ki, MD
Cell centre
EHL Cell Center, Apgujeong, Gangnam, Seoul
GMP capacity
6,000+ lots a year (CLASS 100)
Pipeline
ADSTEM, RASTEM, PDSTEM, KDSTEM
Published patents
11 filings
Hospital network
~100 in Korea, ~50 overseas
Official site
ehlbio.co.kr

When Thai readers search for Korean stem cells, almost everything that surfaces is a clinic selling injections — most of which buy cells from an outside lab. EHL Bio sits at a different level: it is a hospital with its own in-house research institute and cell-culture laboratories, covering everything from isolating, banking and culturing adult stem cells to developing cell therapeutics and immune cell products. That structure matters, because when a clinic says it uses cells from a GMP lab, the useful follow-up is: which lab, what capacity, and licensed under what? In EHL Bio's case the answer is its own hospital-run lab.

On that question EHL Bio has concrete answers. Its first GMP centre was completed in October 2015 and inspected by Korea's MFDS in 2016; it obtained a CPC licence from Japan's Ministry of Health, Labour and Welfare in 2017; and a second GMP centre finished in April 2019, taking combined capacity to about 500 lots a month, or over 6,000 a year. In 2021 the company states it received Korea's licence No.1 for human cell management and the country's first cell-processing facility licence — permits that only exist since Korea's advanced regenerative medicine law took effect.

Technically the core is autologous adipose-derived mesenchymal stem cells. Fat is chosen because it is easy to obtain in volume, cultures stably, and — being the patient's own tissue — carries little immune-rejection risk. The company justifies intravenous delivery on the grounds that blood vessels reach nearly every tissue, so cells can act where a local injection cannot. The more unusual line is urine-derived stem cells, which the company says express Klotho, the protein widely discussed as an anti-ageing factor, and which underpins the KDSTEM kidney programme.

The pipeline is where careful reading matters. All four products remain investigational, not approved treatments. ADSTEM is furthest along: Phase 1 completed in 2017, Phase 2 approved in 2019, Phase 2 finished in 2023 and a Phase 3 IND filed in 2024. KDSTEM received Phase 1 approval and began dosing in 2023, RASTEM has finished preclinical work and is preparing Phase 1, and PDSTEM is still preclinical. So if anyone offers you 'the ADSTEM atopic dermatitis drug' today, ask plainly whether that means enrolment in a clinical trial or something else entirely.

The side of the business Thai readers meet most often without realising it is EHL-STEM conditioned media, registered internationally under the INCI name Human Adipose Stromal Cell Conditioned Media (application 5-09-2014-2745) and used as a premium cosmetic ingredient. The company publishes January 2016 Dermapro testing showing intracellular melanin down 49%, tyrosinase activity down 45% and collagen synthesis up roughly ninefold. Those are in-vitro, cell-level results rather than guaranteed outcomes on a real face — read them as ingredient data, not a results claim.

On immunotherapy the company scopes its work to six cell types — NK, macrophage, iNKT, dendritic, B and T lymphocytes — and explains innate versus acquired immunity alongside them. In 2016–2017 it states that preclinical safety work on immune cells was completed, running in parallel with exosome research protected by a 2021 patent filing. That is why EHL Bio reads as a full-stack cell therapy company rather than a stem-cell-only shop.

The most verifiable evidence is the patent list. The company publishes 11 filings with dates and application numbers, spanning an adipose harvesting and SVF isolation kit (2016), 15-PGDH inhibitor applications in atopic dermatitis and rheumatoid arthritis, culture methods for cells expressing FoxO and Klotho, and exosomes for skin regeneration. Anyone can check these numbers directly in Korea's KIPRIS patent database. There are also 2016 papers on how human adipose-derived MSCs alleviate atopic dermatitis by regulating B lymphocyte maturation.

For Thai readers weighing cell therapy in Korea, this profile carries three lessons. First, separate the cell manufacturer from the clinic delivering treatment: you pay the clinic, but cell quality belongs to the lab. Second, ask in writing which lab cultured the cells, under what licence, how many cells per dose and what quality testing was done. Third, never conflate a drug in clinical trials with a service that can legally be sold — they sit under different rules, and that is where overseas patients are most often misled.

Everything on this page is compiled from every section of EHL Bio's official site: the corporate introduction, history, GMP centre, therapeutic pipeline, patents and papers, conditioned media, immune cells, target diseases and contact pages. The figures and trial statuses are the company's own published information — not an endorsement of treatment outcomes by Khunkim, and not medical advice. Anyone with an existing condition should consult their treating physician first.

Frequently asked questions

  • What is EHL Bio Hospital and how does it differ from an ordinary stem cell clinic?

    EHL Bio is a Korean hospital specialising in cell therapy, founded in 2012. The key difference is that it operates its own research institute in Uiwang, Gyeonggi-do and its own international-standard laboratories — two GMP plants inspected by Korea's MFDS and holding a Japanese CPC licence, culturing over 6,000 lots a year — rather than relying on outside labs the way ordinary clinics do. Patient care runs through the EHL Cell Center in Apgujeong, Seoul, plus a network of roughly 100 partner hospitals in Korea and 50 overseas.

  • Which type of stem cells does EHL Bio use?

    Mainly autologous adipose-derived mesenchymal stem cells, which underpin ADSTEM, RASTEM and PDSTEM, plus autologous urine-derived MSCs expressing Klotho, which underpin the KDSTEM kidney programme. No embryonic cells are involved.

  • Is ADSTEM already an approved atopic dermatitis treatment?

    No. ADSTEM completed Phase 1 in 2017, was approved for Phase 2 in 2019, finished Phase 2 in 2023 and filed a Phase 3 IND in 2024. If anyone offers treatment with it, ask explicitly whether that means enrolment in an approved clinical trial.

  • What standards do EHL Bio's GMP plants hold?

    Two GMP centres, completed in 2015 and 2019, inspected by Korea's MFDS in 2016, holding a CPC licence from Japan's Ministry of Health, Labour and Welfare since 2017, and — per the company — Korea's licence No.1 for human cell management plus the country's first cell-processing facility licence in 2021. Clean rooms run at CLASS 100.

  • How is EHL-STEM conditioned media different from stem cells?

    Conditioned media is the liquid produced while cells are cultured, not the cells themselves. It carries growth factors such as VEGF, FGF, TGF, PDGF, HGF and EGF, which is why it is used as a cosmetic ingredient under the INCI name Human Adipose Stromal Cell Conditioned Media. It is neither a drug nor a cell transplant.

  • How can Thai patients access EHL Bio treatment?

    The main route is contacting the EHL Cell Center in Apgujeong, Seoul directly, or going through a partner hospital or clinic in its network, which covers Japan, Vietnam, Cambodia and Indonesia. Before committing, ask for documentation naming the culturing lab, its licence, the cell count per dose and the accompanying quality-test results.

  • Which diseases does EHL Bio target?

    Its Cure pages name nine groups: Alzheimer's disease, degenerative arthritis, diabetes, erectile dysfunction, liver cirrhosis, myocardial infarction, COPD, autoimmune disease and atopic dermatitis. These are research targets, not evidence that an approved product exists for each.

  • Where is the EHL Cell Center and how do I get there?

    At the EHL Building, 136 Apgujeong-ro, Gangnam-gu, Seoul 06029 — about 444 m from Apgujeong Station exit 5, phone +82-2-532-9855. The head office and research institute are at Indeokwon IT Valley in Uiwang, Gyeonggi-do.

  • How do ADSTEM, KDSTEM, RASTEM and PDSTEM differ?

    They are four separate cell therapy programmes. ADSTEM uses autologous adipose-derived stem cells for atopic dermatitis; KDSTEM uses autologous urine-derived, Klotho-expressing stem cells for chronic kidney disease; RASTEM targets rheumatoid arthritis and autoimmune disease; PDSTEM targets neurodegenerative disease. Each sits at a different trial stage, so none should be assumed approved.

  • Are autologous adipose stem cells safer than donor cells?

    Autologous cells avoid donor-rejection risk, but that does not make the procedure risk-free: liposuction-related infection, laboratory culture quality, the dose and viability of the returned cells and injection-site reactions all remain. Safety depends more on the lab's licence and GMP standard than on the word autologous.

  • How much does treatment using EHL Bio-manufactured cells cost?

    The company does not publish a per-course list price because it does not sell directly to patients. However, partner clinic/hospital price lists that use EHL Bio cells typically list a standard MSC package starting at about USD 35,000 (around KRW 50 million) for 3 sessions of 300 million cells each, totalling 900 million cells, with cell banking for up to 10 years. That works out to roughly KRW 55,556 per million cells, which is very low compared with global benchmarks. The actual price a patient pays still varies by hospital, number of sessions, cell-banking fees and physician fees. Ask for a written itemised quotation before paying.

  • How does cell banking with EHL Bio work?

    Typically fat is harvested once, the stem cells are isolated and expanded in a GMP plant, then cryopreserved for later sessions without repeating liposuction. Clarify the storage contract length, annual fees, what happens if the company or clinic closes, and the paperwork confirming cell counts and contamination testing for your stored lot.

  • What should I ask before agreeing to cell therapy in Korea?

    At minimum five: which laboratory cultures the cells and under what licence; whether this is approved treatment or enrolment in a clinical trial; whether cell count and viability per dose are stated numerically; whether sterility and endotoxin results for that lot are attached; and which Korean-licensed doctor performs the injection and handles follow-up. If the answers are marketing claims without documents, delay the decision.

Sources

Pipeline, GMP facilities, patents, conditioned-media testing, locations and timeline are all compiled from EHL Bio's official site and re-checked at each update.

Medical cautions

5 points • reviewed 2026-08-25

Expand
  • This article is educational information only — not a diagnosis, prescription, or personal medical advice.
  • Outcomes vary by person, depending on age, underlying conditions, current medication, and the treating doctor's technique.
  • Consult a licensed physician and verify the clinic's licence before deciding on any treatment.
  • Some treatments (certain stem cell therapies in particular) are regulated differently by country — check Thai and Korean rules before travelling.
  • Prices, packages, and service details can change — confirm directly with the provider before paying.

Reviewed and last updated: 2026-08-25

Share this page

Last updated: 2026-08-25 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.

Back to categories
See all articles

Related topics: EHL hospital & lab

See all in this category